Donate Help Contact The AHA Sign In Home
American Heart Association
Hypertension
Search: search_blue_button Advanced Search
Hypertension. 1995;25:866-871

This Article
Right arrow Full Text
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nakamura, T.
Right arrow Articles by Murata, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nakamura, T.
Right arrow Articles by Murata, K.

(Hypertension. 1995;25:866-871.)
© 1995 American Heart Association, Inc.


Articles

Effect of Renal Perfusion Pressure on Renal Interstitial Hydrostatic Pressure and Sodium Excretion

Role of Vasopressin V1 and V2 Receptors

Tetsuya Nakamura; Tetsuo Sakamaki; Toshiaki Kurashina; Kunio Sato; Zenpei Ono; Kazuhiko Murata

From the Second Department of Internal Medicine, Gunma University School of Medicine, Maebashi, Japan.

Correspondence to Tetsuya Nakamura, MD, The Second Department of Internal Medicine, Gunma University School of Medicine, Maebashi, 371, Japan.

Abstract Renal interstitial hydrostatic pressure (RIHP) has recently been cited as an important mediator of pressure natriuresis. Our objective was to determine the roles of vasopressin V1 and V2 receptors in mediating the effects of renal perfusion pressure (RPP) on RIHP and sodium excretion (UNaV). The effects of RPP on renal hemodynamics, RIHP, and UNaV were assessed in control Wistar rats (n=10) and in rats pretreated with intravenous infusion of the specific nonpeptide vasopressin V1 antagonist OPC-21268 (100 µg · kg-1 · min-1; n=8) and the V2 antagonist OPC-31260 (40 µg · kg-1 · min-1; n=10). Increasing RPP from 95 to 118 mm Hg in control rats increased RIHP (6.4±1.0 to 9.9±1.3 mm Hg), UNaV (0.29±0.03 to 0.52±0.05 µEq · min-1 · g-1), urine flow rate (UFR) (5.2±0.3 to 7.6±0.6 µL · min-1 · g-1), and the fractional excretion of sodium (FENa). In rats pretreated with V1 antagonist, similar results were obtained for urine osmolality and the responses of RIHP, UNaV, UFR, and FENa to RPP. V2 antagonist reduced urine osmolality (392±47 compared with 979±88 mOsm · kg-1 in control rats) and enhanced the responses of UNaV (0.43±0.08 to 1.32±0.32 µEq · min-1), UFR (17.8±3.2 to 29.2±3.8 µL · min-1 · g-1), and FENa to RPP, but the RIHP response resembled that observed in the control and V1 antagonist groups. Renal blood flow and glomerular filtration rate did not differ among the three groups.

Our findings indicate that neither V1 nor V2 receptor blockade influences the transmission of RPP into the renal interstitium, although V2 receptor blockade enhances pressure natriuresis. The pressure natriuresis is mediated primarily by increased RIHP, and the enhanced natriuretic response to the V2 antagonist is independent of RIHP.


Key Words: vasopressin • renal blood flow • pressure natriuresis • glomerular filtration rate